# Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

> **NCT03524170** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Bintrafusp Alfa
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03524170
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2022-02-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524170, "Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03524170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*